Crossmark

Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database

Crossref DOI link: https://doi.org/10.1186/s40360-025-00872-9

Published Online: 2025-02-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qing, Guangwei

Ye, Shiyi

Wei, Bo

Yang, Yuanjian
License Information

Text and Data Mining valid from 2025-02-21

Version of Record valid from 2025-02-21
More Information

Article History

Received: 1 November 2024

Accepted: 18 February 2025

First Online: 21 February 2025

Declarations

:

: Not applicable. This project was submitted for review through Advocate Health and was waived as this study was deemed non-human subject related research.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below